title: Epstein-Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation.
abstract: Leukemic Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative diseases (PTLD) following allogeneic hematopoietic stem cell transplantation are extremely rare. We can successfully treat an EBV-associated leukemic lymphoma patient with rituximab, cidofovir, and donor lymphocyte infusion (DLI). In the present case, EBV-specific T cells that were present in the peripheral blood before rituximab administration treatment rapidly increased after DLI in association with a decrease in the EBV-DNA load.
authors.affiliation: Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan. Electronic address: takamaz@staff.kanazawa-u.ac.jp.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takamatsu
authors.affiliation: Department of Pediatrics, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan, Kanazawa, Ishikawa 920-8641, Japan.
authors.forename: Raita
authors.initials: R
authors.lastname: Araki
authors.affiliation: Department of Pediatrics, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan, Kanazawa, Ishikawa 920-8641, Japan.
authors.forename: Ryosei
authors.initials: R
authors.lastname: Nishimura
authors.affiliation: Department of Pediatrics, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan, Kanazawa, Ishikawa 920-8641, Japan.
authors.forename: Akihiro
authors.initials: A
authors.lastname: Yachie
authors.affiliation: Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan.
authors.forename: J Luis
authors.initials: JL
authors.lastname: Espinoza
authors.affiliation: Department of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Japan.
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Okumura
authors.affiliation: Department of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Japan.
authors.forename: Takashi
authors.initials: T
authors.lastname: Yoshida
authors.affiliation: Division of Immunology, Aichi Cancer Center Research Institute, Nagoya, Japan.
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Kuzushima
authors.affiliation: Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan.
authors.forename: Shinji
authors.initials: S
authors.lastname: Nakao
mesh_terms: D000293:Adolescent; D000328:Adult; D000077404:Cidofovir; D003596:Cytosine / Q000031:analogs & derivatives / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000175:diagnosis* / Q000628:therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D004854:Herpesvirus 4, Human; D006801:Humans; D007945:Leukemia, Lymphoid / Q000628:therapy / Q000821:virology*; D017710:Lymphocyte Transfusion; D008232:Lymphoproliferative Disorders / Q000628:therapy*; D008297:Male; D063065:Organophosphonates / Q000627:therapeutic use; D000069283:Rituximab / Q000627:therapeutic use; D014184:Transplantation, Homologous / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D063065:Organophosphonates; D000069283:Rituximab; D003596:Cytosine; D000077404:Cidofovir
keywords: Cidofovir; Donor lymphocyte infusion; Epstein–Barr virus; Post-transplant lymphoproliferative disease; Rituximab